TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

6 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Rheumatoid arthritis

    Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

    Comparing pills versus shots of steroids to control rheumatoid arthritis flares

    📍 Sunnybrook Health Sciences Centre · Toronto, Ontario · Get directions →

    People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightHigh blood pressure

    Impact GLP-1 Agonists Following Bariatric

    Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar

    📍 University of Missouri Hospital · Columbia, MO · Get directions →

    Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Rheumatoid arthritis

    Advanced Therapeutics in Rheumatoid Arthritis (RA)

    Tracking how long two rheumatoid arthritis treatments are kept in adults

    📍 Rheumatology Clinic, St. Joseph's Health Care · London, Ontario · Get directions →

    This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Fibrosis Lessens After Metabolic Surgery

    Testing whether metabolic surgery can reduce liver scarring in obesity

    💵 May compensate

    📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Obesity / overweightHigh blood pressure

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Testing treatments to lower high pressure in liver veins in people with advanced liver disease and

    💵 May compensate

    📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →

    Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    Quantifying Hepatic Mitochondrial Fluxes in Humans

    Measuring liver energy activity in people with type 2 diabetes before and after 16 weeks of insulin

    📍 Texas Diabetes Institute - University Health System · San Antonio, TX · +1 more US site · Get directions →

    In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

    ✓ Study care freePhase 4Ages 18–80Learn more →